About this item:

91 Views | 55 Downloads

Author Notes:

Tarek Moustafa, tarek.moustafa@meduni-graz.at

We thank Judith Sommer, Dagmar Silbert and Silvia Racedo for their excellent technical assistance, the Tarling-Vallim Lab for sharing data from their initial GSK2324 time course experiments, and Dr Anuradha Rao for here assistance with gene expression measurements in UDCA-fed mice. We are also thankful to Alan Hofmann for his steadfast feedback and encouragement.

XD is a co-founder of Escient Pharmaceuticals.

Subjects:

Research Funding:

TM is the recipient of the Andrew K. Burroughs fellowship. This work was supported by the Doctoral College “Metabolic and Cardiovascular Disease” (AZ) of the Austrian Science Fund (FWF, DK-MCD W1226). JKT and PAD were supported by the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases grant DK047987.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Biochemistry & Molecular Biology
  • Biophysics
  • Cell Biology
  • Nuclear receptors
  • Bile acids
  • Enterohepatic, cholestasis, gene expression
  • Metabolism
  • FARNESOID-X-RECEPTOR
  • ISO-BILE ACIDS
  • DEOXYCHOLIC-ACID
  • ISOURSODEOXYCHOLIC ACID
  • URSODEOXYCHOLIC ACID
  • METABOLISM
  • MICROBIOTA
  • EXPRESSION
  • BINDING
  • CHOLESTASIS

Secondary (iso)BAs cooperate with endogenous ligands to activate FXR under physiological and pathological conditions

Show all authors Show less authors

Tools:

Journal Title:

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Volume:

Volume 1867, Number 8

Publisher:

, Pages 166153-166153

Type of Work:

Article | Post-print: After Peer Review

Abstract:

IsoBAs, stereoisomers of primary and secondary BAs, are found in feces and plasma of human individuals. BA signaling via the nuclear receptor FXR is crucial for regulation of hepatic and intestinal physiology/pathophysiology. Aim: Investigate the ability of BA-stereoisomers to bind and modulate FXR under physiological/pathological conditions. Methods: Expression-profiling, luciferase-assays, fluorescence-based coactivator-association assays, administration of (iso)-BAs to WT and cholestatic mice. Results: Compared to CDCA/isoCDCA, administration of DCA/isoDCA, UDCA/isoUDCA only slightly increased mRNA expression of FXR target genes; the induction was more evident looking at pre-mRNAs. Notably, almost 50% of isoBAs were metabolized to 3-oxo-BAs within 4 h in cell-based assays, making it difficult to study their actions. FRET-based real-time monitoring of FXR activity revealed that isoCDCA>CDCA stimulated FXR, and isoDCA and isoUDCA allowed fully activated FXR to be re-stimulated by a second dose of GW4064. In vivo co-administration of a single dose of isoBAs followed by GW4064 cooperatively activated FXR, as did feeding of UDCA in a background of endogenous FXR ligands. However, in animals with biliary obstruction and concomitant loss of intestinal BAs, UDCA was unable to increase intestinal Fgf15. In contrast, mice with an impaired enterohepatic circulation of BAs (Asbt−/−, Ostα−/−), administration of UDCA was still able to induce ileal Fgf15 and repress hepatic BA-synthesis, arguing that UDCA is only effective in the presence of endogenous FXR ligands. Conclusion: Secondary (iso)BAs cooperatively activate FXR in the presence of endogenous BAs, which is important to consider in diseases linked to disturbances in BA enterohepatic cycling.

Copyright information:

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/rdf).
Export to EndNote